Industry-Led Consortia supports industry and academic researchers developing translational evidence for novel therapeutics to expand treatment options for familial and sporadic ALS.
Longitude Prize on ALS supports multidisciplinary teams using AI to discover, prioritise and validate therapeutic targets, seeking the strongest evidence of potential to advance ALS treatment.
The Hoffman ALS Clinical Trial Awards Program supports researchers conducting biomarker-driven early trials of ALS therapies and imaging tracers to advance treatment development and care.
Funds research to develop medical products for treating or curing ALS and other rare neurodegenerative diseases in adults and children.
The Lawrence and Isabel Barnett Drug Development Program supports academic and industry investigators conducting preclinical studies of new or repurposed ALS therapies to advance them toward clinical testing.
NIH plans to support research using data from expanded access protocols that provide investigational treatments to people with ALS; applications are not yet being solicited.